Cleveland Clinic Educational Seminar: Living with Chronic Disease
source: pixabay.com

Cleveland Clinic Educational Seminar: Living with Chronic Disease

On March 11, 2021, Patient Worthy attended an educational seminar hosted by the Cleveland Clinic titled Neuromyelitis Optica Spectrum Disorder (NMOSD): Educational Seminar for Patients, Family Members and Caregivers Focus…

Continue Reading Cleveland Clinic Educational Seminar: Living with Chronic Disease
ENSPRYNG Now Available to Canadians with Neuromyelitis Optica Spectrum Disorder
source: pixabay.com

ENSPRYNG Now Available to Canadians with Neuromyelitis Optica Spectrum Disorder

Health Canada has recently granted market authorization to Hoffman La-Roche Limited for their neuromyelitis optica spectrum disorder treatment, ENSPRYNG. Canada is the first country to offer this medication, and hopefully…

Continue Reading ENSPRYNG Now Available to Canadians with Neuromyelitis Optica Spectrum Disorder
Study Finds That Neuromyelitis Optica Patients Could Face Weakened Bones and Fractures
source: pixabay.com

Study Finds That Neuromyelitis Optica Patients Could Face Weakened Bones and Fractures

According to a story from Neurology Advisor, a recent study has found that patients living with neuromyelitis optica spectrum disorder (NMOSD) are at an increased risk of experiencing bone loss,…

Continue Reading Study Finds That Neuromyelitis Optica Patients Could Face Weakened Bones and Fractures
Satralizumab May Lower Neuromyelitis Optica Spectrum Disorder Relapse in Patients
source: pixabay.com

Satralizumab May Lower Neuromyelitis Optica Spectrum Disorder Relapse in Patients

By Danielle Bradshaw from In The Cloud Copy It has been shown in a recently published trial that satralizumab could potentially reduce the risk of neuromyelitis optica spectrum disorder (NMOSD)…

Continue Reading Satralizumab May Lower Neuromyelitis Optica Spectrum Disorder Relapse in Patients
FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug
mohamed_hassan / Pixabay

FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug

According to a press release from Maryland-based Viela Bio, the US Food and Drug Administration (FDA) recently agreed to review the Company's Biologics License Application for its neuromyelitis optica spectrum…

Continue Reading FDA Begins Review of Biologics License Application for Neuromyelitis Optica Spectrum Disorder Drug